NuriFlex Holdings Inc. and Talken GmbH Sign MoU for Metaverse and NFT Wallet and Platform Project
6.1.2022 20:00:00 EET | Business Wire | Press release
NuriFlex Holdings Inc. (“NuriFlex Holdings”) announced that it has signed a memorandum of understanding (“MoU”) with Talken GmbH (“Talken”). The two companies intend to collaborate in the metaverse token project and the multichain decentralized NFT wallet and its platform (“Project”) in various regions based on robust technology and business development capabilities of the parties.
One of NuriFlex Holdings’ businesses involves the design and development of a blockchain-based metaverse ecosystem to offer various virtual worlds and related digital experiences for various services. NuriFlex Holdings is currently investing in the metaverse project that is expected to launch this year, offering global users participation in its virtual metaverse world where they can create and interact with other users like in real life.
Talken GmbH provides a service called ‘Talken’, which is a multi-chain decentralized NFT wallet supported by one of the largest Korean communities. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken NFT Suite offers various products for every NFT lifecycle stage such as NFT wallet, NFT marketplace, simple NFT minting tool and more.
“We are excited to partner and collaborate with Talken GmbH on our metaverse and NFT platform projects. The blockchain technology experience and business development capabilities that NuriFlex Holdings and Talken GmbH bring together will be a great advantage to successfully accomplish new business opportunities and the initial step to our future token projects,” said Songman Cho, Chairman of NuriFlex Holdings Inc.
“We hope this will be the first of many partnerships to come between Nuri Group and Talken. I trust there will be many synergies to be made between Nuri’s solution for blockchain-based digital services and Talken’s unique multichain NFT platform,” said Minsu Ju, Chief Executive Officer of Talken GmbH.
About NuriFlex Holdings Inc.
Located in Vancouver, BC, Canada, NuriFlex Holdings Inc. is a parent company to the Nuri Group of companies, including NuriFlex Inc. in the USA and NuriFlex Co., Ltd. in South Korea. The NuriFlex Group of companies utilize telecommunication technologies and applications to supply a simple, convergent solution for the utilities industry, payment solution and blockchain-based digital service platform. We provide a complete energy IoT solution which enhances the utility of connected micro and smart grids throughout our clients’ systems. The blockchain embedded solution and service will be NuriFlex Group’s next-generation business. Our existing solutions will be integrated with our blockchain technology to make us one of the top integrated solution providers in the international market. Learn more at www.nuri.ca
About Talken GmbH
Talken is the multi-chain decentralized NFT wallet with the largest community. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken is an open NFT ecosystem bridging untapped NFT enthusiasts in Korea to Talken’s native NFTs and other famous NFTs by protocols such as NBA TopShot, Rarible, OpenSea, and more. Our mission is to push for an inclusive and border-less NFT expansion and empower digital creators and collectors with better tools and services to bring NFT mainstream. Learn more at www.talken.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005002/en/
Contact information
NuriFlex Holdings Inc.
Elizabeth Park, CEO
ir@nuri.ca
www.nuri.ca
Talken GmbH
Minsu Ju, CEO
biz@talken.io
www.talken.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
